MX353635B - Cristal monohidratado de sal de potasio con fimasartan, método para preparar el mismo, y composición farmacéuticas que comprende el mismo. - Google Patents

Cristal monohidratado de sal de potasio con fimasartan, método para preparar el mismo, y composición farmacéuticas que comprende el mismo.

Info

Publication number
MX353635B
MX353635B MX2015004573A MX2015004573A MX353635B MX 353635 B MX353635 B MX 353635B MX 2015004573 A MX2015004573 A MX 2015004573A MX 2015004573 A MX2015004573 A MX 2015004573A MX 353635 B MX353635 B MX 353635B
Authority
MX
Mexico
Prior art keywords
same
potassium salt
fimasartan potassium
pharmacological composition
monohydrate crystal
Prior art date
Application number
MX2015004573A
Other languages
English (en)
Other versions
MX2015004573A (es
Inventor
Han Kim Ji
Hak Kim Je
Kwang Lee Joon
Seok Han Nam
Han Lee Joo
Wan Nam Kyung
Wug Yoo Byoung
Mo Kim Chang
Original Assignee
Boryung Pharm
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boryung Pharm filed Critical Boryung Pharm
Publication of MX2015004573A publication Critical patent/MX2015004573A/es
Publication of MX353635B publication Critical patent/MX353635B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se relaciona con una forma cristalina monohidratada novedosa de una sal de potasio con fimasartan que es excelente en la estabilidad de humedad y temperatura y que tiene un tamaño de partícula cristalina fácil para preparar la formulación y superior homogeneidad. La presente invención proporciona una sal de potasio con fimasartan monohidratada novedosa.
MX2015004573A 2012-10-12 2013-10-11 Cristal monohidratado de sal de potasio con fimasartan, método para preparar el mismo, y composición farmacéuticas que comprende el mismo. MX353635B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20120113848A KR101490329B1 (ko) 2012-10-12 2012-10-12 피마살탄 포타슘염의 일수화물 결정, 그 제조방법, 및 그를 포함하는 약제학적 조성물
PCT/KR2013/009097 WO2014058268A1 (ko) 2012-10-12 2013-10-11 피마살탄 포타슘염의 일수화물 결정, 그 제조방법, 및 그를 포함하는 약제학적 조성물

Publications (2)

Publication Number Publication Date
MX2015004573A MX2015004573A (es) 2015-07-21
MX353635B true MX353635B (es) 2018-01-22

Family

ID=50477658

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015004573A MX353635B (es) 2012-10-12 2013-10-11 Cristal monohidratado de sal de potasio con fimasartan, método para preparar el mismo, y composición farmacéuticas que comprende el mismo.

Country Status (13)

Country Link
EP (1) EP2927226A4 (es)
KR (1) KR101490329B1 (es)
CN (1) CN104854099B (es)
AU (1) AU2013330603B2 (es)
BR (1) BR112015008170A2 (es)
CA (1) CA2887056C (es)
IN (1) IN2015DN03975A (es)
MX (1) MX353635B (es)
MY (1) MY169064A (es)
PH (1) PH12015500794A1 (es)
RU (1) RU2613555C2 (es)
SA (1) SA515360275B1 (es)
WO (1) WO2014058268A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101545268B1 (ko) 2015-02-05 2015-08-20 보령제약 주식회사 정제 및 이의 제조방법
CN105784867B (zh) * 2016-03-28 2019-01-01 北京睿创康泰医药研究院有限公司 用于分析非马沙坦有关物质的hplc方法及这些杂质作参比标准的用途
KR102247408B1 (ko) 2017-09-18 2021-05-03 보령제약 주식회사 피마살탄 프로드러그
KR102402501B1 (ko) * 2018-04-24 2022-05-26 (주)국전약품 피마살탄 트로메타민염 및 이를 포함하는 약제학적 조성물
KR102221856B1 (ko) 2020-10-12 2021-03-02 유니셀랩 주식회사 신규한 피마살탄 결정형의 다형체
KR20230062916A (ko) 2021-11-01 2023-05-09 그린케미칼 주식회사 피마살탄 무수물 a형 결정다형 및 그 제조방법
KR20230062917A (ko) 2021-11-01 2023-05-09 그린케미칼 주식회사 피마살탄 일수화물 b형 결정다형 및 그 제조방법
KR20240146734A (ko) 2023-03-30 2024-10-08 (주) 에프엔지리서치 피마살탄의 신규 염 및 이의 제조방법

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100300566B1 (ko) * 1994-09-17 2001-11-22 조생현 피리미디논유도체와그의제조방법및용도
KR19990081093A (ko) * 1998-04-25 1999-11-15 조생현 피리미디논 화합물, 이를 함유하는 약제학적 조성물 및 이의제조방법
KR100617953B1 (ko) 2000-03-23 2006-08-30 보령제약 주식회사 피리미디논 화합물 및 이의 염의 제조방법
EP1436283B1 (en) * 2001-09-21 2008-01-23 Boryung Pharmaceutical Co., Ltd. Method for preparing pyrimidinone compound and pharmaceutically acceptable salts thereof
KR100521980B1 (ko) * 2002-10-10 2005-10-17 보령제약 주식회사 피리미디논 화합물 및 이의 염의 삼수화물의 제조 방법
MX341450B (es) * 2011-04-12 2016-08-19 Boryung Pharm Composicion farmaceutica antihipertensiva.

Also Published As

Publication number Publication date
RU2015117524A (ru) 2016-12-10
KR20140047483A (ko) 2014-04-22
PH12015500794A1 (en) 2015-06-15
SA515360275B1 (ar) 2017-07-11
CA2887056C (en) 2017-09-05
AU2013330603A1 (en) 2015-05-28
MX2015004573A (es) 2015-07-21
WO2014058268A1 (ko) 2014-04-17
MY169064A (en) 2019-02-12
EP2927226A1 (en) 2015-10-07
IN2015DN03975A (es) 2015-10-02
CN104854099A (zh) 2015-08-19
KR101490329B1 (ko) 2015-02-04
BR112015008170A2 (pt) 2017-07-04
EP2927226A4 (en) 2016-07-13
AU2013330603B2 (en) 2016-03-31
CN104854099B (zh) 2016-11-16
RU2613555C2 (ru) 2017-03-17
CA2887056A1 (en) 2014-04-17

Similar Documents

Publication Publication Date Title
PH12015500794A1 (en) Monohydrate crystal of fimasartan potassium salt, method for preparing same, and pharmacological composition comprising same
IN2015KN00262A (es)
ZA201707452B (en) Cell culture compositions and methods for polypeptide production
MX2015006324A (es) Metodos para la fabricacion de polipeptidos proteoliticamente procesados.
IN2014DN06104A (es)
WO2013060867A3 (en) Production of heterodimeric proteins
IN2013CN09704A (es)
EP2803657A4 (en) CRYSTAL FORM OF PROSTAGLANDINANALOGA AND METHOD OF PREPARING THEREOF AND USE THEREOF
EP2808318A4 (en) CRYSTALLINE FORM OF PROSTAGLANDIN ANALOGUE, PROCESS FOR PREPARING SAME AND USE THEREOF
ZA201401613B (en) Method for producing highly pure platinum powder, as well as platinum powder that can be obtained according to said method, and use thereof
IN2015KN00323A (es)
MX350838B (es) Composicion de sal.
MY180645A (en) Microbial production of fatty amines
EP2994483A4 (en) Methods and compositions related to large scale production of proteins
IN2014DN09097A (es)
EP3038640A4 (en) Substituted urea depsipeptide analogs as activators of the clpp endopeptidase
IN2015DN00085A (es)
MX2012012489A (es) Preparacion de polipeptidos y sales de los mismos.
IN2013MU04056A (es)
WO2014042605A9 (en) New tiotropium bromide crystalline form
IN2013CH05282A (es)
IN2013MU02528A (es)
IN2015DN02513A (es)
IN2013CH04330A (es)
IN2013MU01127A (es)

Legal Events

Date Code Title Description
FG Grant or registration